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ABSTRACT 
The health benefits of bioactive compounds naturally present in foods may 
adversely affected by the gastric fluid and therefore their delivery to the lower 
gastrointestinal tract (small and large intestine) becomes limited, which is 
essential for their desired health benefits. The same problem also exists for 
lactoferrin (Lf), which has numerous biological effects including antibacterial, 
antiviral, antitumor, antifungal, anti-inflammatory, immunomodulatory, 
antioxidant etc. The shells comprising alternate layers of bovine serum 
albumin (BSA) and tannic acid (TA) were tested as Lf encapsulation system 
for oral administration. Lf absorption by freshly prepared porous CaCO3 
particles followed by Layer-by-Layer assembly of the BSA-TA shells and 
dissolution of the CaCO3 cores was suggested as the most efficient and 
harmless Lf loading method. One batch of thus obtained capsules contained 
0.70 mg of intact encapsulated Lf. The capsules showed high stability in 
simulated gastric condition but not in simulated intestinal condition. The 
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1. LITERATURE REVIEWS AND OBJECTIVES 
1.1. Introduction 
From a traditional perspective, foods can be simply descried as natural 
materials that keep living beings alive, healthy and able to populate. 
Throughout the history, several food-processing techniques were developed 
such as drying, salting and fermentation (Gram et al., 2002). The fundamental 
notion behind of all these techniques is the preservation of foods at the earliest 
stages after their production, if possible with the highest nutritional quality, 
which is crucial to prevent food scarcity and even famine. During the last 
century, modern food science provided us nourishing foods with healthy 
ingredients in addition to safer, longer-term quality and enriched taste (Floros, 
2008). By early 1980s, the focus has been on processing foods in such a way 
that the bioactive components desired for certain biological activities are 
preserved during their consumption and assimilation (Floros et al., 2010).  
Many nutrients are vulnerable to heat, oxygen and other physically harsh 
conditions. However, the combination of high temperature and low moisture is 
sometimes inevitable not only to increase shelf life but also to control or 
destroy disease-causing organisms. Since the health-consciousness of people 
is increasing, consumers are more likely to prefer food products that have 
added health benefits (Richardson, 2009). In this manner, the development of 
functional foods are encouraged, which is desired to maintain healthy-being 
and to mitigate diseases by creating various applications of bioactive food 
components (Onwulata, 2013).  
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Functional foods are foods those having potential health benefits when 
being consumed beyond basic nutrition. They offer improved health by their 
bioactive compounds content. Example for bioactive compounds includes 
omega-3, vitamins, fatty acids, antioxidants and probiotics. The term 
‘functional foods’ first arose in Japan (EUFIC, 2006). It has not been 
identified by European legislation yet.  
On top of addressing the nutrient deficiency of food products by food 
processing, decreasing the high consumption of unwanted ingredients 
naturally present in foods such as reactive chemicals (a.k.a. free radicals) are 
great interest of functional food producers. Consumption of nutrient-deficient 
foods have been shown to cause diseases while balanced and healthy foods 
have reduced the risk of disease development (Onwulata, 2013). Food 
producers, for this reason, have responded the increased consumer demand for 
the production of nutrient-dense products by using innovative technology 
(Lindsay, 2000). Therefore, the recent research focus is concentrated on the 
relationships between the bioactive components and their health impact 
besides from processing methods to protect nutrients and convey them to the 
active site of action (Onwulata, 2013). 
Encapsulation is an important mean of conveying active component to the 
right place for maximizing the efficacy of their desired biological activity. 
Encapsulation provides not only delivery but may also increase flavor 
retention, mask undesirable flavor and enhance bioavailability of functional 
components (Onwulata, 2013).  
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1.2. Bioactives 
Bioactive components are components that are found in food in small 
amount and have beneficial impact to maintain health. They are widely 
studied in treatment and prevention of various diseases including 
cardiovascular disease and cancer (Kris-Etherton, 2002). Polyphenols have 
presumably reduce oxidation reaction, which decrease the risk of degenerative 
diseases when consumed with the right amount (Krishnaswamy, Orsat, & 
Thangavel, 2012). According to some studies, antioxidants from fruits and 
vegetables might have cancer fighting activity (Arts and Hollman, 2005; Yu & 
Huang, 2010). The effects of whole grains on cardiovascular disease and type-
2 diabetes, nuts and olives on cardiovascular risk factors, fish oils on coronary 
heart disease and stroke, olive oils and nuts on overall well-being, stroke and 
heart disease are other examples of food components showing bioactivity. In 
summary, functional foods can be personalized to decrease cholesterol level, 
regulate blood pressure, prevent risk of diabetes, promote intestinal microbiota 
and boost immune system (Onwulata, 2013).  
 
1.3. Encapsulation  
Encapsulation is a technique that entraps the bioactives, also known as 
(a.k.a.) the core, within a carrier vehicle, a.k.a. the capsule or shell, to form 
micro or nano-sized capsules. It is used to deliver the active compounds to a 
targeted site (Ann, Hemar, & Ann, 2009; Nedovic, Kalusevic, Manojlovic, & 
Levic, 2011).  
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Capsules smaller than 100 nm are called as nano-capsules, where those in 
micron size are microcapsules. Even though classification can be varied, all 
approaches are based on a building capsules that are on either micron or nano 
size. The morphology of capsules is different from technique to technique. 
Variety in morphology of these capsules is demonstrated in Figure 1.1. A 
bioactive can be covered by wall material, or be dispersed in a continuous 
matrix. There are also capsules with multiple cores or multiple layers. It is 
necessary to comprehend the aim of encapsulation in order to choose right 
matrix and to preserve the active compounds (Ann et al., 2009). 
 
 
Figure 1.1. Morphologic difference between microcapsules: (a) single-
core capsule, (b) dispersed core in continuous matrix, (c) multi-layered 
capsule, (d) binary core capsule and (e) single-core–multi-layered capsule.  
Figure is adapted from Ann, Hemar, & Ann (2009). 
 
Active compounds contribute not only to health but also to flavor and 
texture (Ann et al., 2009). Examples for encapsulated active compounds are 
including flavoring agents (e.g. sweeteners, seasonings, spices, essential oils), 
colors, vitamins, minerals, probiotics, and other functional ingredients (Gibbs 
et al., 1999; Madene et al., 2006). 
Many of the active compounds that have biological benefits require a 
protection while they are stored, processed and transferred to the active site 
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after consumption (Ann et al., 2009). The encapsulation technologies have 
been evolved in food industry to preserve, to develop delivery system and to 
control the release of bioactive components (McClemets et al., 2009; Augustin 
and Sanguansri, 2008; Faulks and Southon, 2008). Encapsulation system 
should be designed in a way that they would not have any negative effect on 
physical and sensorial properties of food, while providing desired health 
benefits. In general, the methods and materials are needed to be selected 
according to the nature of bioactive components to be encapsulated. The 
chemistry and interactions of food components are necessary to understand in 
designing capsules for specific function (Lesmes et al., 2009). Molecular 
weight, conformation, polarity, electrical charges are some of the chemical 
characteristics that molecules may show differences, which lead to differences 
in solubility, stability and interactions of molecules. As a consequence, 
encapsulation system should address particular physical and chemical 
properties.  
There are some requirements for food-grade delivery system to possess. 
First, encapsulation-loading efficiency should be at effective amount of 
bioactive compounds. Second, encapsulation should provide protection of 
functional compounds from any degradation such as oxidation and hydrolysis. 
Third, the releasing of active compounds may have to be a targeted place. This 
can be achieved by stimuli such as pH, ionic strength, temperature etc. 
(McClements et al., 2009).  
Many encapsulation methods have been developed so far. The most 
commonly applied ones in food industry are spray drying, fluidized bed 
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coating, liposome entrapment, complex coacervation etc. (Wang, Jiang, & 
Huang, 2007). All of these methods have their own advantages and 
disadvantages for the encapsulation, protection and delivery of bioactive 
component. Spray drying can be used to produce small micro-sized spheres, 
while fluidized bed coating is providing an even coating (Oxley, 2014). 
Liposomes entrapment is favorable as carrier system when both hydrophilic 
and lipophilic ingredients are to be carried (Chun, Choi, Min, & Weiss, 2013). 
Complex coacervation is used to produce small capsules having liquid 
functional agents. Knowledge of each method and nature of component to be 
encapsulated are essential in order to generate an appropriate encapsulation 
system (Oxley, 2014). Cost, regulation, ease of use, biologically availability 
and compatibility are some of other important factors that need to be 
considered in developing suitable encapsulation/delivery system for certain 
bioactive agents (McClements et al., 2009). 
 
1.4. Targeted delivery 
Targeted delivery of bioactive molecules is one of the key applications of 
encapsulation technology. Although it is being applied many years by 
pharmacology, the application of these systems have recently received wide 
attention in food industry (Lomova et al., 2015; Helena & Marques, 2010; 
Kosaraju, 2005). Delivery of bioactive compounds such as probiotics, 
prebiotics and functional proteins is important because their bioactivity greatly 
depends on the stability and bioavailability of those bioactive compounds. It is 
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important to put an emphasis to the fact that the degradation of such bioactive 
agent during food processing, distribution or storage or in the gastrointestinal 
tract (pH, enzymes, presence of other nutrients) largely limit their desired 
biological activity and hamper potential health benefits as well. Therefore, 
these compounds may require a protection to maintain their structure until the 
consumption and to convey it precisely towards a physiological target. 
Encapsulation technology have increasingly been developing in order to be 
more efficient in protection and control the release of bioactives (Wang et al., 
2007).  
 
1.5. Polyelectrolyte capsules 
As a recently developed encapsulation technique, polyelectrolyte capsules 
(PECs) offers a useful platform for controlled release applications as well (De 
Geest, Sanders, Sukhorukov, Demeester, & De Smedt, 2006). PECs are 
formed by electrostatic attractions of two oppositely charged polymers as seen 
in layer-by-layer (LbL) technology. LbL technology is the technique that 
provides the assembly of charged species by consecutive deposition of 
interacting materials on top a substrate material (Decher & Hong, 1991).  
The LbL technology was first established while studying electrostatic 
interaction of counter-charged macromolecules to build multilayered films on 
flat surface (Decher & Hong, 1991). It was then applied around micro-sized 
particles by successive absorption of oppositely charged polyelectrolytes. 
Following this, the colloidal cores were extracted (by dissolution or 
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decomposition) (De Temmerman, Demeester, De Vos, & De Smedt, 2011; 
Sukhorukov, Volodkin, Gu, & Petrov, 2004). 
The advantage of LbL technology is that it offers controlling the shell 
thickness precisely by determining the number of adsorbed molecular layers. 
The permeability of capsule can be manipulated by the varying thickness of 
shell and controlling environmental conditions (Sadovoy et al., 2013; Karahan 
et al., 2014; Kim et al., 2009). 
The controlled release of bioactives can be achieved by a number of 
physical (e.g. magnetic field, electric field, ultrasound, temperature and 
osmotic pressure), chemical (e.g. pH, ionic strength and glucose), and 
biological (enzymes and endogenous receptors) triggers (Kiryukhin, 2014; 
Lopes et al., 2013). The releasing mechanism of capsules applied for food is 
mostly based on pH change, time and/or bacterial fermentation (Cook, 
Tzortzis, Charalampopoulos, & Khutoryanskiy, 2012). The development of 
capsules that decompose in reaction to biological stimuli, such as enzymatic 
cleavage, is of particular significance of many medical, cosmetic, and food 
industries. Enzymatically hydrolyzable capsules formed by PECs have been 
greatly studied for the retention, delivery and release of water-soluble 
bioactives. However, the main disadvantage of such capsules is the use of 
expensive and significantly cytotoxic polycations that limits their food 
application (Lomova et al., 2015). Among the polysaccharide of natural 
origin, chitosan is the only cationic polymer that can be used in the design of 
PECs for food application (Dubruel, 2014). Even it is ideal biopolymer as 
being cheap; chitosan in unmodified form has high solubility in water at acidic 
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pH and therefore not a suitable alternative for the encapsulation of pH 
sensitive payload (Takei et al., 2012; Sobol et al., 2013). Moreover, chitosan 
and its modifications are yet to receive FDA approval for food-related 
applications. Interfacial complexation of biopolymers by hydrophobic 
interaction in addition to hydrogen bonding in layer-by-layer (LbL) assembled 
shells is another approach to form multi-layered capsules with no usage of 
polycations (Lomova, 2015). ). However, since H-bonded systems have more 
complex interactions than electrostatic interactions, one need to understand 
well before applying it to any system (Erel-unal & Sukhishvili, 2008; 
Karahan, Demirel, Kıyılar, & Eyüboglu, 2014).  
In a report done by Sukhorukov et al. (2004), CaCO3 microparticles were 
suggested as a preferable template as they are highly porous, biologically 
compatible, inexpensive and simple to produce and decomposed by mild 
conditions (slightly acidic pH).  Thus, the encapsulation of macromolecules 
into such microcapsules is intensively studied for drug delivery and controlled 
release (Volodkin et al., 2004; Sato, Seno, & Anzai, 2014; Peng et al., 2010, 
Karamitros et al., 2013). Tannic acid (TA), a plant polyphenol of natural 
origin, is a quite popular building block in such assembly. The ability of 
polyphenols to precipitate proteins from solution favors the inclusion of 
proteins in LbL shells (Lomova, 2015). Polyphenolic compounds also increase 
the stability of proteins with their antioxidant activity (Stutava et al., 2006; 
Andrade et al., 2005; Liu et al., 2014).  
Bovine serum albumin (BSA) was used with tannic acid (TA) in formation 
of microcapsules on CaCO3 microparticles. The low cost and biocompatibility 
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make them favorable for their applications in functional food. Proteases found 
in digestive system of human are able to break the peptide bonds in the 
protein/polyphenol films, therefore disrupting the complex and releasing the 
load. BSA-TA based capsules are able to release the load in response to α-
chymotrypsin treatment (Lomova et al., 2015), one of the major pancreatic 
proteases (Bowen, 2006). To improve encapsulation yield, a high molecular 
weight polymer, poly-L-lysine, was used as the precursor layer.  The precursor 
layer provides mechanical integrity to the capsules upon the cores dissolution. 
Protein/polyphenol complexes are most frequently based on hydrophobic 
interactions and hydrogen bonding. However, when polyelectrolytes encounter 
proteins/peptides in charged state like positively-charged polyamino acids 
(e.g. poly-L-lysine), the interaction is predominantly electrostatically-driven 
(Volodkin, Larionova, & Sukhorukov, 2004). The phenolic group is an 
excellent hydrogen donor forming hydrogen bonds with the proteins’ carboxyl 
groups that are stronger than hydrophobic interactions at normal temperatures 
and low ionic strength. When TA and BSA are not charged, there interactions 
take place predominantly through hydrogen bondings. Importantly, such 
multilayers made by protein/polyphenol multilayers are prone to 
enzymatically triggered degradation, which is essential for oral administration 
of active compounds. 
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1.6. Lactoferrin 
The name lactoferrin is derived from a protein in milk, which is binding to 
iron (Adlerova, Bartoskova, & Faldyna, 2008). Lactoferrin (Lf) is a whey 
protein that has many health benefits that make it potential as a functional 
ingredient in food. The biological effects of Lf are quite vast including 
antibacterial, antiviral, antitumor, antifungal, anti-inflammatory, 
immunomodulatory, analgesic, antioxidant, enhancement of lipid metabolism 
to name a few (Bengoechea et al., 2011; Onishi et al., 2007; Balcão, 2013; 
Yao et al., 2013; Onishi, 2011; Brock, 2012). In addition, it is inexpensive and 
has no known toxic side effect to human. Due to its various health benefits, Lf 
is used as supplement in functional foods in Japan, Korea, Indonesia and 
Holland. The commercial bovine lactoferrin supplemented products are 
generally dairy products such as infant formula, UHT milk, and yogurt 
(Egashira et al., 2007; Soejima et al., 2017). The quantity of bovine lactoferrin 
supplementation has been specified by U.S. Food and Drug Administration as 
100 mg/serving  (Palmano et al., 2011). However, processing conditions might 
cause degradation of lactoferrin because of heat treatment in pasteurization 
and use of the starter proteases and pH change in fermentation (Palmano et al., 
2011). In addition, as most proteins, Lf is sensitive to enzymatic digestion of 
the gastrointestinal tract, which results in degradation decreasing its potential 
bioactivity. As a consequence, the orally delivered Lf may have the 
bioavailability as small as  <1% (Yao, Bunt, Cornish, Quek, & Wen, 2013).   
Lf is greatly influenced by a gastric digestive enzyme, pepsin, which 
breaks it into several large fragments, but if reaches intestine it may exist for a 
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few hours (Onishi, 2011). For this reason, the use of protection systems for Lf 
has been investigated with great interest by various studies (Balcão et al., 
2013; David-Birman, Mackie, & Lesmes, 2013; Ma et al., 2013). However, 
the major drawback of all these systems were the use of organic solvents and 
harsh encapsulation conditions that, in the case of Lf, may result in a 
significant loss of its activity (Onishi, 2011). Therefore, there are some 
consideration needs to be taken into account while designing a system for 
delivery of Lf orally. First, it should be safe and biocompatible. Second, 
loading efficiency should be high enough n order for Lf to be effective. Last, 
Lf should retain its beneficial activities during processing of such system (Yao 
et al., 2013). 
 
1.7. Aims and Objectives 
1.7.1. Aims 
The aims of this project are to study LbL-assembled BSA-TA shells for 
lactoferrin encapsulation and deliver Lf in native form to intestine.  
1.7.2. Objectives 
The aims will be achieved by satisfying the following objectives: 
1. Performing in vitro digestion study of Lf.  
2. Developing the best approach for Lf loading in native form to 
capsulate. 
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3. Studying the behavior of capsules under simulated gastrointestinal 
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2. METHODOLOGY 
2.1. Materials 
The bioactive lactoferrin consisting of a puriﬁed extract (lactoferrin 
content of 96.0 %) from bovine whey was donated by Tatua (New Zealand). 
Poly-L-lysine hydrochloride (PLL, Mw 15,000 – 30,000), BSA lyophilised 
powder (≥96%), TA (ACS grade), BSA conjugated with fluorescein 
isothiocyanate (BSA/FITC), tetramethylrhodamine isothiocyanate labeled 
dextran (dextran TRITC), bile salts (for microbiology), pancreatin from 
porcine pancreas (≥ 100 USP U/mg), pepsin from porcine gastric mucosa 
(3802 U/mg), mini protease inhibitor cocktail cOmplete™, hydrochloric acid, 
calcium chloride dehydrate, sodium bicarbonate (for molecular biology), 
sodium chloride, sodium hydroxide, acetonitrile (for HPLC, ≥99.9%) were all 
purchased from Sigma-Aldrich. Anhydrous sodium carbonate (ACS, 99.5% 
min) was purchased from Alfa Aesar. 0.1% aqueous solution of trifluoroacetic 
acid (TFA, LC/MS grade, ≥99.99%) was purchased from VWR Chemicals. 
DQ™ Red BSA was purchased from Molecular Probes Inc, USA. All 
chemicals were used as received without further purification. Deionized (DI) 
water (with specific resistivity higher than 18.2 MΩcm) was obtained by 
Milli-Q plus 185 (Millipore) water purification system, which was used to 
prepare all solutions throughout the studies. 
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2.2. Preparation of Lf-loaded microcapsules 
BSA-TA capsules loaded with proteins (lactoferrin, or, in some 
experiments, dextran-TRITC), were prepared with the assistance of a CaCO3 
sacrificial template, as depicted in Figure 2.1. Spherical porous CaCO3 
particles with an average diameter of ~3 µm (corresponding SEM images are 
available in Figure 2.2) were synthesized according to Volodkin et al. (2004). 
In brief, 0.6 mL of 1M CaCl2 and Na2CO3 solutions was injected into 1.8 mL 
of DI water under vigorous agitation. 2 min later, agitation was stopped and 
resulted dispersion of particles was separated by centrifugation and washed 
two times with DI water. Then the remaining particles were redispersed in Lf 
(1.8 mL, 30 mg/mL in DI water) aqueous solution and shaken over 15 min, 
followed by centrifugation and two washing steps to remove unabsorbed 
proteins. In a co-precipitation protocol, 1.8 mL of an aqueous protein solution 
(30 mg/mL Lf) was mixed with 0.6 mL of 1M CaCl2 solution followed by 
injection of 1M Na2CO3 (0.4-0.6 mL) under vigorous agitation, centrifugation 
and two times washing by DI water.  
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Figure 2.1. Scheme of co-synthesis method (Approach 1) and adsorption 
method (Approach 2) for loading of lactoferrin (Lf) into BSA-TA capsules 




Layer-by-Layer assembly of BSA-TA shell was performed as following. 
First, CaCO3 microparticles with absorbed proteins were immersed in 2 mL of 
2 mg/mL PLL solution in order to generate the first layer (a.k.a. precursor or 
anchoring) that ensures the integrity of the capsules (Lomova et al., 2015). 
After 15 min of continuous shaking, the microparticles were collected by 
centrifugation and residual PLL was removed by washing them twice with DI 
water. Further alternating layers of BSA (5 mL, 2 mg/mL) and TA (5 mL, 3 
mg/mL) were introduced with two steps of washing in-between. This 
procedure was repeated to achieve four bilayers, which corresponds to eight 
layers in total. In some experiment, BSA-FITC was used as one layer instead 
of BSA. Finally, the particles were redispersed in DI water and CaCO3 was 
dissolved by adding 1M HCl solution dropwise until pH reaches ~3.0. The 
resulted capsules were collected by centrifugation and washed two times with 
DI water. 


























Figure 2.2. SEM images of (from top to bottom) CaCO3 microparticles, 
CaCO3 / (BSA-TA)4 and (BSA-TA)4, respectively. All the particles have 
diameters of ~4 µm. 
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2.3. In vitro digestion studies 
In vitro digestibility analysis was used to obtain a reliable understanding in 
predicting the behavior of bioactive components in a real digestion system. 
Simulated digestion system was designed to mimic physiological conditions of 
in vivo, considering the digestive enzymes and their concentrations, pH, 
digestion time, and salt concentrations, among other factors (Minekus et al., 
2014). In this study, in vitro digestion system includes gastric and intestinal 
digestion 
Capsules behavior under simulated gastrointestinal conditions has been 
studied at 37 °C under continuous agitation using the following protocol 
(Minekus et al., 2014). NaCl solution (4.0 mL of 150 mM) at pH 3.0 (acidified 
by HCl) was added to 5.0 mL of a dispersion containing encapsulated 
lactoferrin. Then 1 mL of 7.1 mg/mL pepsin solution containing 150 mM of 
NaCl at pH 7.0 was injected there. This was considered as a starting point for 
digestion, which is simulated gastric fluid (SGF). At 60 min of digestion, pH 
of the solution was increased to 7.0, then 1.0 mL of 120 mM bile salts 
(containing 0.1 M NaHCO3 solution at pH 7.0) and 1.0 ml of 0.1, 0.3 and 1.2 
mg/mL pancreatin solution were added, separately in different sample 
solutions. To stop digestion at a selected point of time, a protease inhibitor 
tablet was added and the solution was frozen at -20oC before further analysis. 
For weight loss experiments, all the samples were treated with 1.2 mg/ml 
pancreatin solution in simulated intestinal fluid (SIF). Then, after SIF was 
completed, the solutions were frozen and the capsules were separated by 
centrifugation, washed two times with DI water and freeze-dried. 
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2.4. Characterization  
Lf concentration was measured by high performance liquid 
chromatography (HPLC) using a Waters 2695 Alliance System equipped with 
2996 photo diode array detector. The column was Phenomenex Aeris XB-C8, 
particle diameter 3.6 µm WIDEPORE, 4.6 × 100 mm2. Prior to analysis, all 
the samples were filtered through a 0.45 µm syringe filter, the injection 
volume of sample was 50 µL and detection wavelength was at 210 nm. A 
continuous gradient elution at 35 °C and 1.0 ml/min flow rate was performed 
with 0.1% aqueous TFA solution (mobile phase A) and 90% acetonitrile – 
10% aqueous TFA solution (mobile phase B) as following: the percentage of 
the mobile phase B was increased linearly from 20 to 50% by 15 min, then 
decreased back to 20% by 20 min of elution. All of the experiments were done 
in triplicate. Calibration curve was plotted by using the area of peak at 9.5 min 
retention time of different concentration of Lf standard solution as 0.01, 0.06, 
0.2, 0.5, 1.0 mg/ml, respectively (Figure 2.3 and 2.4). Calibration curve was 
used to measure Lf concentration from the area of peak at 9.5 min retention 
time. A linear regression and its equation were shown in Figure 2.4 in red 
colour. However, Lf concentration was determined by using the line obtained 
from the joint of two consecutive data points as it seen in Figure 2.4 in black 
colour.  
Scanning electron microscopy (SEM) analysis was performed using a 
JEOL LVSEM 6360LA. Samples were prepared by depositing a drop of a 
particle or capsule suspension on a silicon wafer and allowing it to dry at room 
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temperature. Before imaging, the samples were coated with approximately 5 
nm gold film using a Denton sputter-coater. 
Confocal micrographs were taken with a LSM800 Zeiss confocal laser-
scanning microscope, equipped with a 100 x oil immersion objective.  
 
 
Figure 2.3. HPLC chromatograms of lactoferrin standard solutions with 
concentrations 0.01 mg/mL (1), 0.06 mg/mL (2), 0.2 mg/mL (3), 0.5 mg/mL 
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3. RESULTS AND DISCUSSION 
3.1. In vitro digestion study of native Lf 
Gastric and intestinal digestion of Lf was studied by using in vitro 
simulated digestive model of Minekus et al. (2014). In vitro digestion system 
of Lf includes gastric and intestinal digestion only. The concentration of Lf in 
an unknown sample was calculated using calibration curve (Figure 2.4). 
Lf was first treated with SGF for 10, 30 and 60 min, respectively. The 
degradation profile of Lf showed a quicker degradation in SGF. It was 
observed that Lf has degraded almost completely after 10 min incubation in 
SGF (Figure 3.1).  
How long food stays in the stomach varies greatly between people and 
even in the same person at different times and after different composition of 
the meal. However, there is estimation can be taken as the total time required 
for emptying stomach is 4 to 5 hours (Camilleri et al., 1989). Therefore, from 
this estimation, we can conclude that Lf would not be available for intestinal 
transit. A rapid degradation of Lf in SGF could be due to the presence pepsin 
enzyme and/or lower pH of gastric fluid. In each scenario, Lf completely 
destroyed in the stomach fluid and therefore not able to reach to the small 
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Figure 3.1. HPLC chromatogram of lactoferrin (Lf) (1.0 mg/mL) before and 
after (a) 10 min (b) 30 min (c) 60 min of simulated gastric fluid (SGF). 
 
 
The concentration of pancreatin in intestinal fluid varies from person to 
person depending on the factors such as age, gender and dietary preferences 
(Fieker et al., 2011). Therefore, when studying SIF, pancreatin was introduced 
(b) (c) 
(a) 
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into solution with different concentrations as 0, 0.1, 0.3 and 1.2 mg/mL, 
respectively. It was observed that when there was no pancreatin in SIF, Lf 
remained almost intact within the 60 min of incubation (Table 3.1). However, 
when introducing the pancreatin into the solution, Lf was digested as shown in 
the HPLC chromatogram result (Figures 3.2, 3.3 and 3.4). When the 
concentration of pancreatin was as low as 0.1 mg/mL, Lf still remained at high 
amount and slightly decreased from 0.66 to 0.42 mg/mL after 10 and 60 min of 
SIF, respectively. However, when it was increased to three times higher 
concentration, 0.3 mg/mL, the peak corresponding the Lf showed a sudden 
decrease and almost no peak observed by 60 min of SIF. Even after 10 min of 
digestion, more than 80% of Lf was digested and almost degraded by 30 min. 
The degradation behaviour of Lf in SIF with different pancreatin concentration 
was demonstrated in Figure 3.5. With 1.2 mg/mL pancreatin concentration, 
only 5% of Lf was observed after 10 min and no more at 30 and 60 min of 
incubation (Figures 3.2, 3.3 and 3.4). This result showed that Lf could be 
considered to be highly and rapidly digestible in vitro digestion model. It was 
also reported by Yao et. al. (2013) that Lf could be completely degraded in 
gastric and the small intestinal digestion in vivo in humans. However, the 
percentages of digestion result reported here cannot be interpreted as the 
percentage in vivo as vivo is much more complex system. The presence of 
other food components like soluble fibers might have lowering effect on the 
rate of Lf proteolysis as well (David-Birman et al., 2013). 
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Figure 3.2. HPLC chromatograms of lactoferrin (Lf) (1.0 mg/mL) before 
(black) and after 10 min simulated intestinal fluid SIF, with 0 (red), 0.1 (green), 








 29  
 
 
Figure 3.3. HPLC chromatograms of lactoferrin (Lf) (1.0 mg/mL) before 
(black) and after 30 min simulated intestinal fluid (SIF), with 0 (red), 0.1 
(green), 0.3 (blue) and 1.2 (pink) mg/mL pancreatin solution, respectively. 
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Figure 3.4. HPLC chromatograms of lactoferrin (Lf) (1.0 mg/mL) before 
(black) and after 60 min simulated intestinal fluid (SIF), with 0 (red), 0.1 
(green), 0.3 (blue) and 1.2 (pink) mg/mL pancreatin solution 
 
 
Table 3.1. The concentration of lactoferrin (mg/mL) with initial concentration 
of 1.0 mg/ml after 10, 30 and 60 min of simulated gastric fluid (SGF) and 









Pancreatin concentration (mg/mL) 
0 0.1 0.3 1.2 
10 min 0.005 0.90 0.66 0.16 0.05 
30 min - 0.90 0.53 0.02 - 
60 min - 0.90 0.02 - - 
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Figure 3.5. The degradation kinetic curve of lactoferrin (Lf) in simulated 
intestinal fluid with 0 (black), 0.1 (red), 0.3 (green) and 1.2 (blue) mg/mL 
pancreatin concentration, respectively. 
 
 
In order to enhance the bioavailability of Lf, we need to utilise a protection 
system that preserves the structure (i.e. native form) of Lf from the degradation 
of SGF, hence it would possible to deliver it to its targeted place. The capsule 
designed in such a way that Lf remains intact in SGF but gets digested in SIF 
and thus release the payload in small intestine would do this specific task. In 
the following part, whether BSA-TA shells provide this particular function or 
not will be determined after an elaborate characterization will be performed.  
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3.2. Characterization of capsules   
Fluorescence Microscopy has been used to observe whether our designed 
capsules were able to capture and hold the payload inside the shells. Here, 
BSA-FITC was used as one of the component of shell wall and dextran-
TRITC as core material while making capsules in order to obtain fluorescence 
under microscopy. TRITC stained core material bright orange and FITC 
stained wall material green. Similar methodologies have been used many 
researchers in LbL literature for different purposes successfully, which makes 
the technique quite reliable (Kozlovskaya, Ok, Sousa, Libera, & Sukhishvili, 
2003; Tsukruk et al., 2011). The fluorescence microscopy images of capsules 
showed that dextran was successfully encapsulated into the shells since the 
shapes of orange and green colored capsules on image were almost identical 
(Figure 3.6). Therefore, Lf loading was introduced to capsule as next step after 
its successful loading into CaCO3. 
 
 
Figure 3.6.  Fluorescence microscope images of BSA(FITC)-TA capsules 
loaded with dextran-TRITC 
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3.3. Lactoferrin loading efficiency into CaCO3 microparticles 
In this work, encapsulation of Lf was performed by using porous CaCO3 
microparticles as first suggested by Volodkin et al. (2004). Here we applied 
two different approaches for loading of Lf into CaCO3, as shown in Figure 
1.1. In the first approach, microparticles produced in the presence of Lf 
solution (30 mg/mL), while in the second approach CaCO3 particles were first 
formed and then put in contact with the same concentration of Lf aqueous 
solution after washing. Before measuring the amount of loaded Lf, the 
particles were washed two times in DI water and then dissolved in HCl 
solution. Then the concentration of released Lf was measured by using HPLC. 
Table 3.2 shows the efficiency of Lf loading. (Note that respective calibration 
curves and chromatograms are available in Figure 2.3 and 2.4). 
 
Table 3.2. Amount of loaded lactoferrin (Lf) from HPLC measurements.  
Approach Weight of CaCO3 
microparticles, mg 
Amount of 





48  1.2 ± 0.3  2.5 ± 0.6 
Post-loading 60 
300 
0.7 ± 0.1  
4.1 ± 1.5  
1.2 ± 0.2 
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In co-precipitation approach, CaCO3 template usually formed by using 
stoichiometric amounts of Na2CO3 and CaCl2 (Lomova et al., 2015; Volodkin, 
Larionova, & Sukhorukov, 2004). However, if co-precipitation is performed in 
this fashion, the pH of resulted solution is highly alkaline that may damage Lf. 
For example, treatment Lf with NaOH solution resulted in complete 




Figure 3.7. HPLC chromatograms of lactoferrin (Lf) before and after 
treatment with NaOH, 1.0 M, respectively. 
 
Therefore, in order to protect Lf from any risk of potential degradation, the 
pH of reaction mixture in the co-precipitation approach was adjusted to pH 8.0 
using higher ratio of CaCl2 concentration to that of Na2CO3 of 1.5:1.0. In this 
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case, 2.5 wt.% of absorbed intact Lf was detected. However, the 
chromatograms of respective samples have much broader peak at retention 
time of 9.5 min (compared to standard Lf solution) with some other intense 
peaks at the lower retention times (Figure 3.8). A possible reason to explain 
this could be the partial hydrolysis of Lf and its breakdown into smaller 
fragments. For this reason, post-loading approach has been applied by forming 
CaCO3 particles first and washing two times with DI water to remove all salts 
and reduce pH to neutral. Lf solution was then introduced to CaCO3 particles. 
The respective chromatogram (Figure 3.8) had a narrower peak at 9.5 min 
corresponding to the native form of Lf with another narrow peak of similar 
intensity at a lower retention time of 8.3 min. Those results suggested us that 
some of Lf molecules breakdown upon the adsorption onto the particles, 
although to a significantly lower extent than in co-precipitation approach. 
However, the overall amount of loaded Lf and its fragments in this case was 
lower than in co-precipitation approach (0.7 mg vs. 1.2 mg). The reason of this 
high loading might be explained by steric hindrance for the protein molecules 
to diffuse into the CaCO3 microparticles during adsorption as the pore size of 
CaCO3 (20–60 nm) and protein (3–10 nm) is comparable. In other words, it 
can be also interpreted as that the dimensions of proteins were big enough to 
released out of pores when the protein entrapped inside of CaCO3 particles by 
co-synthesis (Balabushevich, Lopez De Guerenu, Feoktistova, Skirtach, & 
Volodkin, 2016). Another possible explanation could be the presence of 
“closed” pores (with no exit on the particles surface) that were not available 
for Lf in post-loading method but could be filled with Lf in co-precipitation 
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approach. As a result, more Lf was encapsulated by co-precipitation approach 
with both intact and damaged fragments, but post-loading approach provided 
less damage with reasonably high amount of encapsulated intact Lf. 
Therefore, post-loading approach was selected in following experiments since 
it was determined less harmful to Lf and resulted in reasonably high amount of 
encapsulated intact Lf. The amount of encapsulated Lf was found constant 
when 5 times more CaCO3 particles were introduced into the Lf solution with 
~ 1.2-1.4 wt.% of encapsulated Lf (see Table 3.2). This observation leaded us 
to conclude that the concentration of Lf solution (30 mg/mL) was likely high 
enough to fill all of microparticles with Lf to their full capacity.  
In summary, post-loading approach was selected for following experiment 
since it was determined less harmful to Lf and resulted in reasonably high 
amount of encapsulated intact Lf. In the next experiment, in-vitro digestion of 
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Figure 3.8. HPLC chromatograms of lactoferrin (Lf) released from CaCO3 
microparticles upon their dissolution at pH 3.0. Lf was co-precipitated with 48 
mg CaCO3 at pH 8.0 (1); Lf was post-loaded to 60 (2) and 300 (3) mg of 
CaCO3. Chromatogram of a standard Lf solution in DI water (4) is given for 
comparison (1.0 mg of Lf in 6.0 mL, same volume as in the samples). 
 
3.4. In vitro digestion study of Lf/PLL/(BSA-TA)4 shells 
The weight change profile of Lf/PLL/(BSA-TA)4 shells in gastrointestinal 
fluid was evaluated by using in vitro simulated digestive model (Minekus et 
al., 2014). Table 3.3 shows the weights of (BSA-TA)4 capsules, as prepared 
and upon simulated digestion, both for Lf-loaded and empty capsules. The 
weights were measured after freezing and drying of the all capsules.  
LbL assembly of the BSA-TA shell has been performed on the surface of 
CaCO3/Lf particles followed by dissolution of the core material (CaCO3) with 
HCl. It is important to mention that introduction of a polycation (PLL) as the 
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first anchor layer was necessary to provide mechanical integrity to the 
capsules upon the cores dissolution. Figure 11-a shows SEM image of resulted 
capsules.  As it is seen in Table 3.3, the capsules loaded with Lf were almost 
two times heavier than empty capsules. This could be an indication of 
successful inclusion of Lf (both intact and its fragments) in the capsules. 
Morphology differences of microspheres studied by SEM also showed the 
increase in volume of capsules when there was Lf payload (Figure 3.9). As 
also highlighted in Figure 3.9, the capsules’ volumes are bigger generally in 




Figure 3.9. SEM images of capsule (a) without and (b) with lactoferrin. 
 
The capsules loaded with Lf kept its weight stable and did not degrade in 
the simulated gastric fluid as the observed weight loss after 60 min of 
treatment was still within experimental error (Table 3.3). SEM analysis also 
(a) (b) 
SEM  
Capsule w/o Lf Capsule with 
Lf 
SEM  
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did not show significant changes in the capsules size or shell integrity (Figure 
10-a and b). The accordance on the results of weight loss experiment and SEM 
analysis of SGF treatment confirmed the stability of capsule in SGF. However, 
quick degradation of the capsules occurred in capsules with and without Lf 
after SIF with ~70% and ~90% loss of the initial weight after 3 min, 
respectively. And, it is important to note that almost complete digestion took 
place after 10 min of treatment (Table 3.3). This complete digestion means 
that both the material capsule’s made of and Lf itself are fully digestible in 
simulated intestinal environment by almost 10 min. The degradation kinetic of 
(BSA-TA)4 capsules with and without Lf during SIF treatment was shown in 
Figure 3.13. From Figure 3.13, even though it might be seen that capsules 
degraded faster when they had no Lf payload than when they have payload, 
there is actually statically no significant difference between two. Student’s t 
test was applied to evaluate whether or not there is a statistical difference on 
weight loss percentage between capsule with and without Lf payload by taking 
the data obtained at 0, 3 and 10 minutes from both. A p-value of ≤0.05 was 
used as the level of significance. The statistical analysis here was performed 
by using Microsoft Excel.  
The confocal images of capsules before and after SIF treatment (Figure 
3.11 and 3.12, respectively) also confirmed that complete degradation of 
capsules in SIF. When comparing the capsule images in Figure 3.11 and 3.12, 
the dispersion of FITC in Figure 3.12 was observed, which was the indication 
of the breakdown of capsules’ integrity. The reason for such a sharp change in 
the stability of shells is the fact that the cleavage sites specificity of pepsin and 
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pancreatin are different. BSA is more susceptible to pancreatin because it 
cleaves peptide chains mainly at the carboxyl terminal of the amino acids 
lysine or arginine, and their total amount in BSA is rather high (18.72% (Stein 
et al., 1949). In contrast, pepsin preferentially cleaves peptide amide bonds 
when large hydrophobic amino acid (tyrosine, tryptophan, or phenylalanine) 
are at the carboxyl side, and BSA contains only 6.56% of phenylalanine, 
5.06% of tyrosine, and 0.58% of tryptophan (Stein et al., 1949). Such 
differences naturally reflect themselves as variations in their degradation 
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Table 3.3. Weight and corresponding weight loss of lactoferrin (Lf) / (BSA-
TA)4 capsules upon their treatment with simulated gastric fluid (SGF) and 

































 Weight, mg  Weight loss, % 
CaCO3 / (BSA-TA)4 317.2 ± 6 - 
(BSA-TA)4 15 ± 2 - 
SIF, 1 min 2.5 ± 1 83.3 
SIF, 3 min 1.53 ± 0.65 89.8 
SIF, 10 min 0.03 ± 0.06 99.8 
Lf / (BSA-TA)4 32.1 ± 3 - 
SGF, 60 min 30.6 ± 1 5 
SIF, 3 min 9 ± 2 72 
SIF, 10 min 1.10 ± 0.08 96.6 
SIF, 60 min 0.9 ± 0.6 97.2 













Figure 3.10. SEM images of lactoferrin / (BSA-TA)4 capsules after core 
dissolution (a), 60 min of treatment in simulated gastric fluid (b) and 3 min of 




























Figure 3.11. The confocal microscopy images of capsules, before simulated 
intestinal fluid, represent (a) BSA-FITC as one of the shell layer, (b) dextran 




















Figure 3.12. The confocal microscopy images of capsules, after simulated 
intestinal fluid, represent (a) BSA-FITC as one of the shell layer, (b) dextran 
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Figure 3.13. The degradation kinetic of (BSA-TA)4 capsules with (black) and 










 46  
3.5. Conclusion and Outlook 
We have been demonstrated that Lf was not able to sustain its structure in 
intact form during simulated digestion model because the digestive system is 
designed to hydrolyze protein into its fragments. This limits the absorption of 
Lf and taking away its potential health benefits. 
 
In this work for the first time we introduced the LbL assembled (BSA-TA) 
microcapsules as a system for encapsulation and oral delivery of Lf as 
bioactive ingredient to the intestine. The efficiency encapsulation system was 
demonstrated by in vitro digestion model and SEM analysis. Absorption by 
freshly prepared porous CaCO3 microparticles followed by LbL assembly of 
the BSA-TA shell and dissolution of the cores was suggested as the most 
efficient and less harmful Lf loading method. One batch of thus obtained 
CaCO3 microparticles (60 mg) contained 0.70 mg of intact encapsulated Lf. 
The capsules showed high stability in simulated gastric conditions by keeping 
its weight stable and did not degrade in the simulated gastric digestion as the 
observed weight loss after 60 min of treatment was still within experimental 
error. SEM images also confirmed that capsules showed high stability in 
simulated gastric conditions and therefore able to protect encapsulated Lf from 
gastric digestion. The capsules degraded in the simulated intestinal conditions 
releasing the proteins in their beneficial place of action.  
We believe that suggested encapsulation system has a great potential for 
oral delivery of a number of active food ingredients, including Lf and other 
bioactive components such as natural inhibitors of glycoside hydrolases and 
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many other ingredients that require protection from gastric digestion and 
release in the intestine to achieve their bioactivity. However, to translate our 
findings into actual practical use, it would be necessary to further optimize the 
method proposed here in this study. For instance, even for the case of Lf, 
which we had specifically focused in this study, in order to verify the potential 
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